CONTEXT THERAPEUTICS INC
NASDAQ: CNTX (Context Therapeutics Inc.)
Last update: 2 days ago, 5:09PM0.660
0.01 (1.37%)
| Previous Close | 0.651 |
| Open | 0.652 |
| Volume | 87,365 |
| Avg. Volume (3M) | 249,483 |
| Market Cap | 59,222,712 |
| Price / Book | 0.640 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 |
| Diluted EPS (TTM) | -0.280 |
| Total Debt/Equity (MRQ) | 0.21% |
| Current Ratio (MRQ) | 48.80 |
| Operating Cash Flow (TTM) | -15.22 M |
| Levered Free Cash Flow (TTM) | -36.90 M |
| Return on Assets (TTM) | -38.01% |
| Return on Equity (TTM) | -55.59% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Context Therapeutics Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -1.0 |
| Average | 1.13 |
|
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.33% |
| % Held by Institutions | 79.93% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mpm Bioimpact Llc | 31 Mar 2025 | 14,705,882 |
| Avidity Partners Management Lp | 31 Mar 2025 | 7,477,200 |
| Blue Owl Capital Holdings Lp | 31 Mar 2025 | 7,367,906 |
| Great Point Partners I Lp | 31 Mar 2025 | 4,683,711 |
| Woodline Partners Lp | 31 Mar 2025 | 1,361,188 |
| Ally Bridge Group (Ny) Llc | 31 Mar 2025 | 1,157,448 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 9.00 (D. Boral Capital, 1,263.22%) | Buy |
| Median | 6.50 (884.55%) | |
| Low | 4.00 (Piper Sandler, 505.88%) | Buy |
| Average | 6.50 (884.55%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 0.712 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 26 Jun 2025 | 4.00 (505.88%) | Buy | 0.651 |
| D. Boral Capital | 08 May 2025 | 9.00 (1,263.22%) | Buy | 0.773 |
| 29 Apr 2025 | 9.00 (1,263.22%) | Buy | 0.881 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Jun 2025 | Announcement | Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting |
| 29 May 2025 | Announcement | Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer |
| 12 May 2025 | Announcement | Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 07 May 2025 | Announcement | Context Therapeutics Reports First Quarter 2025 Operating and Financial Results |
| 05 May 2025 | Announcement | Context Therapeutics Announces Chief Medical Officer Transition |
| 30 Apr 2025 | Announcement | Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting |
| 09 Apr 2025 | Announcement | Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95 |
| 01 Apr 2025 | Announcement | Context Therapeutics to Participate in Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |